組織診斷:各種技術與全球市場
市場調查報告書
商品編碼
1642870

組織診斷:各種技術與全球市場

Tissue Diagnostics: Technologies and Global Markets

出版日期: | 出版商: BCC Research | 英文 124 Pages | 訂單完成後即時交付

價格

全球組織診斷市場規模預計將從 2024 年的 89 億美元增加到 2029 年的 124 億美元,預測期間的複合年成長率為 7.0%。

組織診斷試劑領域預計將從 2024 年的 66 億美元成長到 2029 年的 93 億美元,預測期內的複合年成長率為 6.9%。預計亞太市場規模將從 2024 年的 22 億美元成長到 2029 年的 31 億美元,複合年成長率為 7.0%。

本報告調查了全球組織診斷市場,並提供了市場概況的摘要、市場影響因素和市場機會的分析、法律制度、新興技術和技術發展的趨勢、市場規模的趨勢和預測、各個細分市場和地區的詳細分析、競爭格局以及主要企業的概況。

目錄

第1章執行摘要

  • 市場展望
  • 研究範圍
  • 市場概況

第2章 市場概況

  • 市場概況與定義
  • 免疫組織化學 (IHC)
  • 原位雜合反應
  • 聚合酵素鏈鎖反應
  • 次世代定序
  • 一般文化測試

第3章 市場動態

  • 市場動態
  • 市場促進因素
  • 癌症發生率增加
  • 癌症治療中的伴同性診斷
  • 早期癌症篩檢的重要性
  • 提高對癌症早期症狀的認知
  • 高齡化社會
  • 市場機會
  • 增強訪問
  • 數位病理學
  • 夥伴關係
  • 市場限制
  • 組織診斷測試的費用
  • 競爭技術
  • 旅行時間
  • 市場挑戰
  • 專業技能人才短缺
  • 複雜的樣品製備與處理

第4章 新興科技與發展

  • 概述
  • 數位病理學與人工智慧整合
  • 3D 組織病理學和 AI
  • 螢光定序

第5章 組織診斷測試市場

  • 細分市場
  • 市場區隔
  • 按產品類型分類的市場
  • 市場區隔:按技術
  • 市場區隔:按細分市場
  • 組織病理市場
  • 分子病理市場
  • 微生物檢測市場
  • 數位病理市場
  • 市場區隔:按應用
  • 市場區隔:按最終用戶
  • 地理分佈
  • 市場區隔:按地區
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 其他地區

第6章 競爭訊息

  • 產業場景
  • 競爭格局

第 7永續性。

  • ESG:簡介
  • 環境績效
  • 社會績效
  • 管治績效
  • BCC的結語

第 8 章 附錄

  • 調查方法
  • 參考
  • 縮寫詞
  • 公司簡介
  • ABBOTT
  • AGILENT TECHNOLOGIES INC.
  • BD
  • BIOCARE MEDICAL LLC.
  • BIOMERIEUX
  • BIO-RAD LABORATORIES INC.
  • DANAHER CORP.
  • F. HOFFMANN-LA ROCHE LTD.
  • ILLUMINA INC.
  • KONINKLIJKE PHILIPS NV
  • MERCK KGAA
  • MYRIAD GENETICS INC.
  • QIAGEN
  • THERMO FISHER SCIENTIFIC INC.
  • ZYTOVISION GMBH
Product Code: MDS051B

The global market for tissue diagnostics is estimated to increase from $8.9 billion in 2024 to reach $12.4 billion by 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 through 2029.

The reagents market for tissue diagnostics is estimated to increase from $6.6 billion in 2024 to reach $9.3 billion by 2029, at a CAGR of 6.9% from 2024 through 2029.

The instruments market for tissue diagnostics is estimated to increase from $2.2 billion in 2024 to reach $3.1 billion by 2029, at a CAGR of 7.0% from 2024 through 2029.

Report Scope

The report provides an analysis of the tissue diagnostics market, along with a competitive landscape and profiles of leading companies that include their revenues, product portfolios and recent activities. The report analyzes market dynamics, including drivers, limitations, challenges and opportunities, and discusses current and potential market size. The report will enable companies in the industry to make informed decisions about the production and licensing of goods and services. Organizations, distributors and exporters should find useful information about market developments and trends.

The study segments the market on multiple bases. By product type, the market is segmented into instruments and reagents (reagents/test kits/consumables of tissue diagnostics).

By segment type, the market is divided into histopathology, which includes hematoxylin and eosin stains (H&E) and immunohistochemistry (IHC); molecular pathology, which includes in situ hybridization (ISH), polymerase chain reaction (PCR) and next-generation sequencing (NGS); microbiological testing, which includes general culture testing and antimicrobial susceptibility testing and identification (AST/ID); and digital pathology.

Regional market analysis is provided for all the major segments. The regions are North America; Europe; Asia-Pacific; Latin America; and Rest of the World (RoW), which in this report consists of the Middle East and Africa. The report also provides country-level analyses of markets and market segments.

The report covers only tissue sample-based tests. The liquid biopsy market; swab, saliva and urine-based tests; and the service testing market of tissue diagnostics are outside the scope of the report.

In this report, the tissue diagnostics market is segmented by:

Product type:

  • Reagents.
  • Instruments.

Segments:

  • Histopathology (H&E, IHC).
  • Molecular pathology (ISH, PCR and NGS).
  • Microbiological testing (general culture testing, AST/ID testing) .
  • Digital pathology.

Technology:

  • H&E.
  • IHC.
  • ISH.
  • PCR.
  • NGS.
  • Digital pathology.

Applications:

  • Oncology.
  • Tissue typing.
  • Pathogen detection and AST.

End users:

  • Professional laboratories.
  • Emergency care units.
  • Academic and research institutes.

Report Includes

  • 40 data tables and 42 additional tables
  • An analysis of the global market trends for tissue diagnostics, with market revenue data from 2022 to 2023, estimates for 2024, forecasts for 2025, and projected CAGRs through 2029
  • Estimates of the size and revenue prospects of the global market, along with a market share analysis by type of test, technology, application, end user and region
  • Facts and figures pertaining to the market dynamics, technical advances, regulations, and the impact of macroeconomic factors
  • Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
  • An analysis of patents, emerging trends and developments in the industry
  • Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
  • Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
  • Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Danaher Corp., Agilent Technologies Inc., Thermo Fisher Scientific Inc., and Illumina Inc.

Table of Contents

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary

Chapter 2 Market Overview

  • Market Overview and Definitions
  • Immunohistochemistry (IHC)
  • In Situ Hybridization
  • Polymerase Chain Reaction
  • Next-Generation Sequencing
  • General Culture Testing

Chapter 3 Market Dynamics

  • Market Dynamics
  • Market Drivers
  • Increasing Incidence of Cancer Cases
  • Companion Diagnostics in Cancer Treatment
  • Importance of Early Cancer Testing
  • Raising Awareness of Early Signs of Cancer
  • Aging Population
  • Market Opportunities
  • Enhancing Access
  • Digital Pathology
  • Partnerships
  • Market Restraints
  • Cost of Tissue Diagnostic Tests
  • Competing Technologies
  • Turnaround Time
  • Market Challenges
  • Lack of Skilled Professionals
  • Complex Sample Preparation and Handling

Chapter 4 Emerging Technologies and Developments

  • Overview
  • Digital Pathology and AI Integration
  • 3D Tissue Pathology and AI
  • Fluorescent In Situ Sequencing

Chapter 5 Tissue Diagnostics Testing Market

  • Segmentation Breakdown
  • Market Breakdown
  • Market Breakdown, by Product Type
  • Market Breakdown, by Technology
  • Market Breakdown, by Segment
  • Histopathology Market
  • Molecular Pathology Market
  • Microbiology Testing Market
  • Digital Pathology Market
  • Market Breakdown, by Application
  • Market Breakdown, by End User
  • Geographic Breakdown
  • Market Breakdown, by Region
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Rest of the World

Chapter 6 Competitive Intelligence

  • Industry Scenario
  • Competitive Landscape

Chapter 7 Sustainability in the Market for Tissue Diagnostics: An ESG Perspective

  • Introduction to ESG
  • Environmental Performance
  • Social Performance
  • Governance Performance
  • Concluding Remarks from BCC

Chapter 8 Appendix

  • Research Methodology
  • References
  • Acronyms
  • Company Profiles
  • ABBOTT
  • AGILENT TECHNOLOGIES INC.
  • BD
  • BIOCARE MEDICAL LLC.
  • BIOMERIEUX
  • BIO-RAD LABORATORIES INC.
  • DANAHER CORP.
  • F. HOFFMANN-LA ROCHE LTD.
  • ILLUMINA INC.
  • KONINKLIJKE PHILIPS N.V.
  • MERCK KGAA
  • MYRIAD GENETICS INC.
  • QIAGEN
  • THERMO FISHER SCIENTIFIC INC.
  • ZYTOVISION GMBH

List of Tables

  • Summary Table : Global Tissue Diagnostics Market, by Product Type, Through 2029
  • Table 1 : Global Incidence of All Cancers, by Region, 2022-2045
  • Table 2 : Cancer Cases, by Country, 2022
  • Table 3 : Incidence of Cancer, by Cancer Type, 2022
  • Table 4 : Cancer Treatments Based on Specific Tests
  • Table 5 : Global Tissue Diagnostics Market, Through 2029
  • Table 6 : Global Tissue Diagnostics Market, by Product Type, Through 2029
  • Table 7 : Global Tissue Diagnostics Market, by Technology, Through 2029
  • Table 8 : Global IHC Tissue Diagnostics Market, by Region, Through 2029
  • Table 9 : Global H&E and Special Stains Diagnostics Market, by Region, Through 2029
  • Table 10 : Global ISH Tissue Diagnostics Market, by Region, Through 2029
  • Table 11 : Global PCR Tissue Diagnostics Market, by Region, Through 2029
  • Table 12 : Global NGS Tissue Diagnostics Market, by Region, Through 2029
  • Table 13 : Global Digital Pathology Market, by Region, Through 2029
  • Table 14 : Global Tissue Diagnostics Market, by Segment Type, Through 2029
  • Table 15 : Global Histopathology Market, by Product Type, Through 2029
  • Table 16 : Global Histopathology Market, by Region, Through 2029
  • Table 17 : Global Molecular Pathology Market, by Product Type, Through 2029
  • Table 18 : Global Molecular Pathology Market, by Region, Through 2029
  • Table 19 : Global Microbiology Testing Market, by Product Type, Through 2029
  • Table 20 : Global Microbiology Testing Market, by Region, Through 2029
  • Table 21 : Global Digital Pathology Market, Through 2029
  • Table 22 : Global Digital Pathology Market, by Region, Through 2029
  • Table 23 : Global Tissue Diagnostics Market, by Application, Through 2029
  • Table 24 : Global Tissue Diagnostics Market, by End User, Through 2029
  • Table 25 : Global Tissue Diagnostics Market, by Region, Through 2029
  • Table 26 : North American Tissue Diagnostics Market, by Country, Through 2029
  • Table 27 : European Tissue Diagnostics Market, by Country, Through 2029
  • Table 28 : Asia-Pacific Tissue Diagnostics Market, by Country, Through 2029
  • Table 29 : Latin American Tissue Diagnostics Market, by Country, Through 2029
  • Table 30 : RoW Tissue Diagnostics Market, Through 2029
  • Table 31 : ESG: Environmental Overview
  • Table 32 : ESG: Social Overview
  • Table 33 : ESG: Governance Overview
  • Table 34 : Acronyms Used in this Report
  • Table 35 : Abbott: Company Snapshot
  • Table 36 : Abbott: Financial Performance, FY 2022 and 2023
  • Table 37 : Abbott: Product Portfolio
  • Table 38 : Agilent Technologies Inc.: Company Snapshot
  • Table 39 : Agilent Technologies Inc.: Financial Performance, FY 2022 and 2023
  • Table 40 : Agilent Technologies Inc.: Product Portfolio
  • Table 41 : Agilent Technologies Inc.: News/Key Developments, 2024
  • Table 42 : BD: Company Snapshot
  • Table 43 : BD: Financial Performance, FY 2022 and 2023
  • Table 44 : BD: Product Portfolio
  • Table 45 : Biocare Medical LLC.: Company Snapshot
  • Table 46 : Biocare Medical LLC.: Product Portfolio
  • Table 47 : Biomerieux: Company Snapshot
  • Table 48 : Biomerieux: Financial Performance, FY 2022 and 2023
  • Table 49 : Biomerieux: Product Portfolio
  • Table 50 : Bio-Rad Laboratories Inc.: Company Snapshot
  • Table 51 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2022 and 2023
  • Table 52 : Bio-Rad Laboratories Inc.: Product Portfolio
  • Table 53 : Danaher Corp.: Company Snapshot
  • Table 54 : Danaher Corp.: Financial Performance, FY 2022 and 2023
  • Table 55 : Danaher Corp.: Product Portfolio
  • Table 56 : Danaher Corp.: News/Key Developments, 2023
  • Table 57 : F. Hoffmann-La Roche Ltd.: Company Snapshot
  • Table 58 : F. Hoffmann-La Roche Ltd.: Financials, FY 2022 and 2023
  • Table 59 : F. Hoffmann-La Roche Ltd.: Product Portfolio
  • Table 60 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024
  • Table 61 : Illumina Inc.: Company Snapshot
  • Table 62 : Illumina Inc.: Financial Performance, FY 2022 and 2023
  • Table 63 : Illumina Inc.: Product Portfolio
  • Table 64 : Illumina Inc.: News/Key Developments, 2024
  • Table 65 : Koninklijke Philips N.V.: Company Snapshot
  • Table 66 : Koninklijke Philips N.V.: Financial Performance, FY 2022 and 2023
  • Table 67 : Koninklijke Philips N.V.: Product Portfolio
  • Table 68 : Merck KGaA: Company Snapshot
  • Table 69 : Merck KGaA: Financial Performance, FY 2022 and 2023
  • Table 70 : Merck KGaA: Product Portfolio
  • Table 71 : Myriad Genetics Inc.: Company Snapshot
  • Table 72 : Myriad Genetics Inc.: Financial Performance, FY 2022 and 2023
  • Table 73 : Myriad Genetics Inc.: Product Portfolio
  • Table 74 : QIAGEN.: Company Snapshot
  • Table 75 : QIAGEN.: Financial Performance, FY 2022 and 2023
  • Table 76 : QIAGEN.: Product Portfolio
  • Table 77 : Thermo Fisher Scientific Inc.: Company Snapshot
  • Table 78 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
  • Table 79 : Thermo Fisher Scientific Inc.: Product Portfolio
  • Table 80 : ZytoVision GmbH: Company Snapshot
  • Table 81 : ZytoVision GmbH: Product Portfolio

List of Figures

  • Summary Figure A : Global Tissue Diagnostics Market, by Product Type, 2021-2029
  • Summary Figure B : Shares of Global Market for Tissue Diagnostics, by Product Type, 2023
  • Figure 1 : Market Dynamics of Tissue Diagnostics
  • Figure 2 : Shares of All Cancer Cases, by Region, 2022
  • Figure 3 : Emerging Trends and Technologies in Tissue Diagnostics
  • Figure 4 : Shares of Global Market for Tissue Diagnostics, by Technology, 2023
  • Figure 5 : Shares of Global Market for Tissue Diagnostics, by Segment Type, 2023
  • Figure 6 : Shares of Global Market for Histopathology, by Product Type, 2023
  • Figure 7 : Shares of Global Market for Molecular Pathology, by Product Type, 2023
  • Figure 8 : Shares of Global Market for Microbiology Testing, by Product Type, 2023
  • Figure 9 : Shares of Global Market for Tissue Diagnostics, by Application, 2023
  • Figure 10 : Shares of Global Market for Tissue Diagnostics, by End User, 2023
  • Figure 11 : Shares of Global Market for Tissue Diagnostics, by Region, 2023
  • Figure 12 : Shares of North American Market for Tissue Diagnostics, by Country, 2023
  • Figure 13 : Shares of European Market for Tissue Diagnostics, by Country, 2023
  • Figure 14 : Shares of Asia-Pacific Market for Tissue Diagnostics, by Country, 2023
  • Figure 15 : Shares of Latin American Tissue Diagnostics Market, by Country, 2023
  • Figure 16 : Shares of Global Market for Tissue Diagnostics, by Company, 2023
  • Figure 17 : ESG Pillars
  • Figure 18 : Advantages of ESG for Companies
  • Figure 19 : Abbott: Revenue Shares, by Business Unit, FY 2023
  • Figure 20 : Abbott: Revenue Shares, by Country/Region, FY 2023
  • Figure 21 : Agilent Technologies Inc.: Revenue Shares, by Business Unit, FY 2023
  • Figure 22 : Agilent Technologies Inc.: Revenue Shares, by Country/Region, FY 2023
  • Figure 23 : BD: Revenue Shares, by Business Unit, FY 2023
  • Figure 24 : BD: Revenue Shares, by Country/Region, FY 2023
  • Figure 25 : Biomerieux: Revenue Shares, by Business Unit, FY 2023
  • Figure 26 : Biomerieux: Revenue Shares, by Country/Region, FY 2023
  • Figure 27 : Bio-Rad Laboratories Inc.: Revenue Shares, by Business Unit, FY 2023
  • Figure 28 : Bio-Rad Laboratories Inc.: Revenue Shares, by Country/Region, FY 2023
  • Figure 29 : Danaher Corp.: Revenue Shares, by Business Unit, FY 2023
  • Figure 30 : Danaher Corp.: Revenue Shares, by Country/Region, FY 2023
  • Figure 31 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
  • Figure 32 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
  • Figure 33 : Illumina Inc.: Revenue Shares, by Business Unit, FY 2023
  • Figure 34 : Illumina Inc.: Revenue Shares, by Country/Region, FY 2023
  • Figure 35 : Koninklijke Philips N.V.: Revenue Shares, by Business Unit, FY 2023
  • Figure 36 : Koninklijke Philips N.V.: Revenue Shares, by Country/Region, FY 2023
  • Figure 37 : Merck KGaA: Market Shares, by Business Unit, FY 2023
  • Figure 38 : Merck KGaA: Revenue Shares, by Country/Region, FY 2023
  • Figure 39 : Myriad Genetics Inc.: Revenue Shares, by Business Unit, FY 2023
  • Figure 40 : Myriad Genetics Inc.: Revenue Shares, by Country/Region, FY 2023
  • Figure 41 : QIAGEN.: Revenue Shares, by Business Unit, FY 2023
  • Figure 42 : QIAGEN.: Revenue Shares, by Country/Region, FY 2023
  • Figure 43 : Thermo Fisher Scientific Inc.: Revenue Shares, by Business Unit, FY 2023
  • Figure 44 : Thermo Fisher Scientific Inc.: Revenue Shares, by Country/Region, FY 2023